{"filing":{"accession_number":"0001213900-26-073699","cik":"0002023311","ticker":"AAPG","company_name":"ASCENTAGE PHARMA GROUP INTERNATIONAL","form":"6-K","filing_date":"2026-06-30","report_date":null,"primary_document":"ea0296418-6k_ascentage.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2023311/000121390026073699/ea0296418-6k_ascentage.htm"},"events":[{"id":15096,"run_id":13464,"accession_number":"0001213900-26-073699","anchor_item_number":"EX-99.1","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"This announcement discloses a further grant of restricted stock units (RSUs) and share options under three equity compensation schemes (2021 RSU Scheme, 2022 RSU Scheme, and Post IPO Share Option Scheme) to directors, senior management, employees, and service providers. The disclosure includes specific grant details, vesting schedules, performance conditions, and clawback mechanisms. The grants to directors (including non-executive and independent non-executive directors) and senior management constitute material executive compensation arrangements requiring disclosure under Item 5.02(e) equivalent standards.","company_name":"ASCENTAGE PHARMA GROUP INTERNATIONAL","ticker":"AAPG","filing_date":"2026-06-30","form":"6-K","submitted_at":null,"items":[{"id":12731,"accession_number":"0001213900-26-073699","item_number":"EX-99.1","item_title":"ea029641801ex99-1.htm","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This announcement discloses a further grant of restricted stock units (RSUs) and share options under three equity compensation schemes (2021 RSU Scheme, 2022 RSU Scheme, and Post IPO Share Option Scheme) to directors, senior management, employees, and service providers. The disclosure includes specific grant details, vesting schedules, performance conditions, and clawback mechanisms. The grants to directors (including non-executive and independent non-executive directors) and senior management constitute material executive compensation arrangements requiring disclosure under Item 5.02(e) equivalent standards.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-01T02:25:29.469018+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":12731,"accession_number":"0001213900-26-073699","item_number":"EX-99.1","item_title":"ea029641801ex99-1.htm","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This announcement discloses a further grant of restricted stock units (RSUs) and share options under three equity compensation schemes (2021 RSU Scheme, 2022 RSU Scheme, and Post IPO Share Option Scheme) to directors, senior management, employees, and service providers. The disclosure includes specific grant details, vesting schedules, performance conditions, and clawback mechanisms. The grants to directors (including non-executive and independent non-executive directors) and senior management constitute material executive compensation arrangements requiring disclosure under Item 5.02(e) equivalent standards.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-01T02:25:29.469018+00:00","company_name":"ASCENTAGE PHARMA GROUP INTERNATIONAL","ticker":"AAPG","filing_date":"2026-06-30"}]}